Research Topics
| S R MehtaSummaryAffiliation: McMaster University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trialShamir R Mehta
McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
Lancet 376:1233-43. 2010..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI...- Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelinesShamir R Mehta
Division of Cardiology, Department of Medicine and the Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
J Invasive Cardiol 14:27E-34E; quiz 35E. 2002.... - Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CUREShamir R Mehta
Hamilton Health Sciences, General Division, 237 Barton Street East, McMaster Clinic, Room 508, Hamilton, Ontario, Canada, L8L 2X2
J Invasive Cardiol 15:17B-20B; discussion 20B-21B. 2003 - Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategyShamir R Mehta
McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
Am Heart J 156:1080-1088.e1. 2008.... - Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to AssShamir R Mehta
McMaster University, Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
Circulation 118:2038-46. 2008..Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported... - Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trialShamir R Mehta
Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
J Am Coll Cardiol 50:1742-51. 2007..This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial... - Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trialShamir R Mehta
Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
JAMA 293:437-46. 2005..Given the potential global importance of GIK infusion, a large, adequately powered randomized trial is required to determine the effect of GIK on mortality in patients with STEMI... - Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomesShamir R Mehta
Department of Medicine, Mc Master University, Hamilton Health Sciences, Hamilton, ON, Canada
Can J Physiol Pharmacol 83:98-103. 2005..Despite this worse prognosis, patients with ACS developing CHF are less likely to be referred for invasive management... - Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot TrialShamir R Mehta
McMaster University and the Population Health Research Institute, Hamilton Health Sciences, General Division, 237 Barton St E, Hamilton, Ontario, Canada L6K 1B8
Circulation 111:1390-7. 2005..We performed a randomized trial to determine the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting... - Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary interventionShamir R Mehta
Division of Cardiology, McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
J Am Coll Cardiol 41:79S-88S. 2003.... - Early versus delayed invasive intervention in acute coronary syndromesShamir R Mehta
Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
N Engl J Med 360:2165-75. 2009..Earlier trials have shown that a routine invasive strategy improves outcomes in patients with acute coronary syndromes without ST-segment elevation. However, the optimal timing of such intervention remains uncertain... - Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trialsShamir R Mehta
Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada L6K 1B8
JAMA 293:2908-17. 2005.... - Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyS R Mehta
Division of Cardiology, the Population Health Research Institute and the Canadian Cardiovascular Collaboration Project Office, McMaster University, Hamilton, Canada
Lancet 358:527-33. 2001..We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI... - Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving >18 000 patientsL Cronin
Preventive Cardiology and Therapeutics Program and the Division of Cardiology, McMaster University, Hamilton, Canada
Circulation 104:269-74. 2001..95; P=0.0001). CONCLUSIONS: In this large cohort of patients with ACS, stroke was an uncommon but serious event associated with high mortality. The performance of early CABG surgery was a powerful independent predictor of stroke... - Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trialJ A M Anderson
Division of Hematology, and Cardiology, Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada
J Thromb Haemost 8:243-9. 2010..The mechanism of lower bleeding and improved efficacy with fondaparinux is uncertain... - Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)studyJ W Eikelboom
Preventive Cardiology and Therapeutics Program, McMaster University, Hamilton, Canada
Circulation 103:643-50. 2001..The excess of major bleeding in hirudin-treated patients who develop thrombocytopenia suggests that thrombocytopenia may contribute to the increased risk of bleeding observed with hirudin... - Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarctionS R Mehta
Division of Cardiology, Hamilton Health Sciences Corporation, McMaster University, Ontario, Canada
J Am Coll Cardiol 37:37-43. 2001..We sought to evaluate the prognostic impact of right ventricular (RV) myocardial involvement in patients with inferior myocardial infarction (MI)... - Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary interventionS R Mehta
Division of Cardiology, Hamilton Health Sciences Corporation, McMaster University Medical Center, 1200 Main Street West, HSC 3U5, Hamilton, Ontario, Canada L8N 3Z5
Eur Heart J 23:117-23. 2002.... - Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trialSanjit S Jolly
McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
Lancet 377:1409-20. 2011..We aimed to assess whether radial access was superior to femoral access in patients with acute coronary syndromes (ACS) who were undergoing coronary angiography with possible intervention... - Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapyJ W Eikelboom
McMaster University, Hamilton General Hospital McMaster Clinic, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2
JAMA 285:444-50. 2001..Recent studies have reported disagreement between meta-analysis of small trials and subsequent large trials addressing the same question. However, disagreement for uncommon but serious adverse safety outcomes has not been examined... - Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trialsJohn W Eikelboom
General Division, Hamilton Health Sciences, Hamilton, Ontario, Canada
Circulation 112:3855-67. 2005..These data suggest that LMWH should be the preferred antithrombin in this setting... - Comparison of fondaparinux and enoxaparin in acute coronary syndromesSalim Yusuf
Population Health Research Institute, McMaster Clinic, Hamilton General Hospital, 237 Barton St. East, Hamilton, ON L8L 2X2, Canada
N Engl J Med 354:1464-76. 2006..ClinicalTrials.gov number, NCT00139815.)... - Routine early angioplasty after fibrinolysis for acute myocardial infarctionWarren J Cantor
Southlake Regional Health Centre, Newmarket, ON, Canada
N Engl J Med 360:2705-18. 2009..The role and optimal timing of routine PCI after fibrinolysis have not been established... - Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE studySanjit S Jolly
Department of Medicine, McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, Canada
Eur Heart J 30:900-7. 2009..In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin is uncertain. We evaluated the safety of different doses of aspirin after PCI... - Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6Ganesan Karthikeyan
Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada
Expert Rev Cardiovasc Ther 7:241-9. 2009..This clinical trial report discusses the findings of these two pivotal trials... - Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarctionAbhinav Goyal
Population Health Research Institute, Hamilton Health Sciences, Ontario, Canada
Am Heart J 157:763-70. 2009..Both a history of diabetes mellitus and elevated inhospital glucose levels predict death after acute myocardial infarction (AMI). However, only diabetes history (and not glucose levels) is routinely considered in AMI risk assessment... - Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) triaSanjit S Jolly
Department of Medicine, Hamilton Health Sciences, Population Health Research Institute, McMaster University, McMaster Clinic Room 630, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario L8L 2X2, Canada
J Am Coll Cardiol 54:468-76. 2009..This study sought to evaluate the relative safety and efficacy of fondaparinux and enoxaparin in patients with acute coronary syndromes (ACS) treated with glycoprotein (GP) IIb/IIIa inhibitors or thienopyridines... - Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trialsSanjit S Jolly
Department of Medicine, Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
Am Heart J 157:132-40. 2009..The objective of this meta-analysis was to determine if radial access reduces major bleeding and as a result can reduce death and ischemic events compared to femoral access... - Early and late effects of clopidogrel in patients with acute coronary syndromesSalim Yusuf
Population Health Research Institute and Division of Cardiology, McMaster University, Hamilton, Canada
Circulation 107:966-72. 2003..We examine the benefits and risks associated with the use of adding clopidogrel to aspirin within the first 30 days and later (31 days to 12 months) in 12 562 patients with ACS... - The risks of waiting for cardiac catheterization: a prospective studyMadhu K Natarajan
Division of Cardiology, Population Health Research Institute, McMaster University, Hamilton, Ont
CMAJ 167:1233-40. 2002..A secondary objective was to identify predictors of cardiac events that occur while patients are waiting... - Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stentsJeremy S Paikin
McMaster University, Hamilton, Ontario, Canada
Med J Aust 192:487-8. 2010..Decisions regarding the use of triple therapy should take into account the balance between thromboembolism and bleeding risk in individual patients... - Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventionsMadhu K Natarajan
Division of Cardiology, Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
Am J Cardiol 93:750-3. 2004.... - Adverse impact of bleeding on prognosis in patients with acute coronary syndromesJohn W Eikelboom
Thrombosis Service, Hamilton Health Sciences, Hamilton, Ontario, Canada
Circulation 114:774-82. 2006..The use of multiple antithrombotic drugs and aggressive invasive strategies has increased the risk of major bleeding in acute coronary syndrome (ACS) patients. It is not known to what extent bleeding determines clinical outcome... - Effects of CYP2C19 genotype on outcomes of clopidogrel treatmentGuillaume Pare
Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
N Engl J Med 363:1704-14. 2010.... - Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevationSalim Yusuf
Population Health Research Institute, Hamilton Health Sciences, Hamilton General Hospital and McMaster University, Hamilton, Ontario, Canada
JAMA 293:427-35. 2005..No antithrombotic or newer antiplatelet drug has been shown to reduce mortality in acute MI... - A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventionsMadhu K Natarajan
Division of Cardiology, Department of Medicine, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada
Am Heart J 151:175. 2006..This study examined the relative effects of dalteparin and UFH on coagulation and angiographic and clinical indices during PCI... - Aspirin resistance and its implications in clinical practiceJohn Eikelboom
McMaster University, Hamilton, Ontario, Canada
MedGenMed 7:76. 2005.... - Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarctionSalim Yusuf
Department of Medicine, McMaster University, and Population Health Research Institute, Hamilton General Hospital, Hamilton, Canada
Am Heart J 148:1068-78. 2004..Although glucose-insulin-potassium (GIK) infusion and low-molecular-weight heparin (LMWH) appear to be promising in AMI, the available trials are inconclusive and these treatments require rigorous evaluation... - Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trialSalim Yusuf
Department of Medicine, McMaster University and Hamilton Health Sciences, McMaster Clinic, Hamilton General Hospital, Hamilton, Ontario, Canada
JAMA 295:1519-30. 2006..The role of additional antithrombotic agents is unclear, especially among patients not receiving reperfusion therapy... - Design and rationale of the radial versus femoral access for coronary intervention (RIVAL) trial: a randomized comparison of radial versus femoral access for coronary angiography or intervention in patients with acute coronary syndromesSanjit S Jolly
McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada
Am Heart J 161:254-260.e1-4. 2011..Radial access versus femoral access has yet to be formally evaluated in a randomized trial adequately powered for the comparison of clinically important outcomes... - Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experienceBehnam Banihashemi
Terrence Donnelly Heart Centre, Division of Cardiology, St Michael s Hospital, University of Toronto, and The Canadian Heart Research Centre, Toronto, Ontario, Canada
Am Heart J 158:917-24. 2009..There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp) IIb/IIIa inhibitors, alone versus combination therapies, in non-ST-elevation acute coronary syndrome (NSTE-ACS)... - In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinasesB H Strauss
Division of Cardiology, St Michael s Hospital, Toronto, Canada
Circ Res 79:541-50. 1996..Our data suggest that degradation of newly synthesized collagen is an important mechanism regulating collagen accumulation and that MMPs have an integral role in collagen turnover after balloon angioplasty... - Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) studyRon J G Peters
Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
Circulation 108:1682-7. 2003..Bleeding risks increase with increasing aspirin dose, with or without clopidogrel, without any increase in efficacy. Our findings suggest that the optimal daily dose of aspirin may be between 75 and 100 mg, with or without clopidogrel... - Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groupsAndrzej Budaj
Postgraduate Medical School, Grochowski Hospital Warsaw, Poland
Circulation 106:1622-6. 2002.... - Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromesShamir R Mehta
Am Heart J 150:1107. 2005..CONCLUSIONS: The MICHELANGELO OASIS 5 program will provide a comprehensive and reliable evaluation of fondaparinux in a broad spectrum of patients with ACS... - Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) studyBasil S Lewis
Lady Davis Carmel Medical Center, Haifa, Israel
Am Heart J 150:1177-84. 2005..In the present study, we examined the relation between clopidogrel therapy, timing of PCI, and cardiovascular (CV) events in patients participating in the CURE study... - Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI)Huyen Tran
Department of Clinical Haematology, Monash Medical Centre, Victoria, Australia
Vasc Health Risk Manag 2:379-87. 2006..Thus, dual antiplatelet therapy with the combination of clopidogrel and aspirin is becoming the new standard of care for the management of patients with STEMI... - Renal function and outcomes in acute coronary syndrome: impact of clopidogrelMatyas Keltai
Gottsegen Gyorgy Hungarian Institute of Cardiology, Department of Cardiology, Semmelweis University, Budapest, Hungary
Eur J Cardiovasc Prev Rehabil 14:312-8. 2007..The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes... - Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromesKeith A A Fox
Cardiovascular Research, University of Edinburgh, Edinburgh, United Kingdom
Ann Intern Med 147:304-10. 2007..Renal dysfunction increases the risk for major bleeding... - Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) TrialKeith A A Fox
Royal Infirmary of Edinburgh, Edinburgh, UK
Circulation 110:1202-8. 2004..Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies also increase the risk of bleeding... - Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trialPaul Kolm
Christiana Care Health System, Newark, Delaware, USA
Can J Cardiol 23:1037-42. 2007.... - Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarctionRafael Diaz
Etudios Cardiologica Latin America, Rosario, Argentina
JAMA 298:2399-405. 2007..While some smaller trials suggest benefit, in the CREATE-ECLA trial, GIK infusion had no effect on 30-day mortality in 20,201 patients... - Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatmentJonas Oldgren
Uppsala Clinical Research Center, Uppsala University Hospital, S 751 85 Uppsala, Sweden
Eur Heart J 29:315-23. 2008..We evaluated fondaparinux treatment vs. usual care, i.e. placebo or unfractionated (UF) heparin, in a pre-specified subgroup of 2867 (out of 12 092) patients not receiving reperfusion treatment in the OASIS-6 trial... - The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trialRon J G Peters
Department of Cardiology, Academic Medical Center, Room F3 236, P O Box 22660, 1100 DD Amsterdam, The Netherlands
Eur Heart J 29:324-31. 2008..In the OASIS-6 trial, fondaparinux significantly reduced mortality and reinfarction without increasing bleeding in 12 092 patients with acute ST elevation MI... - Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor useMarc S Sabatine
Cardiovascular Division, Department of Medicine, Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Am Heart J 155:910-7. 2008..However, the need for clopidogrel pretreatment is debated in patients receiving a glycoprotein IIb/IIIa inhibitor (GPI)... - Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) unstable angina/non-ST elevation myocardial infarction critical pathway toolkitChristopher P Cannon
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Crit Pathw Cardiol 7:43-81. 2008..These materials are being made available online to help physicians, nurses, and hospitals implement the new guidelines and thus improve the quality of care and outcomes for patients with ACS... - Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgeryChristopher P Cannon
Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
Ann Thorac Surg 80:768-79. 2005..Because the bleeding risk with aspirin is dose dependent, use of a low dose is preferred post-CABG...